Ke Liang Xie

Dr. Ke Liang Xie

Tianjin Medical University General Hospital, Tianjin, China
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2012 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QWQiong Wang
Qiong Wang
PLPengcun Li
Pengcun Li
ALAilin Li
Ailin Li
WJWei Jiang
Wei Jiang
HWHong Wang
Hong Wang
Ke Liang XieKe Liang Xie
Ke Liang Xie
Glioblastoma multiforme (GBM) is a highly malignant brain tumor with a poor prognosis. MicroRNAs (miRNAs) are a class of small non-coding RNAs, approximately 21-25 nucleotides in length. Recently, some researchers have demonstrated that plasma miRNAs are sensitive and specific biomarkers of various cancers. The primary aim of the study is to investigate whether miRNAs present in the plasma of GBM patients can be used as diagnostic biomarkers and are associated with glioma classification and clinical treatment. Plasma samples were attained by venipuncture from 50 patients and 10 healthy donors. Plasma levels of miRNAs were determined by real-time quantitative polymerase chain reaction. The plasma levels of miR-21, miR-128 and miR-342-3p were significantly altered in GBM patients compared to normal controls and could discriminate glioma from healthy controls with high specificity and sensitivity. However, these three miRNAs were not significantly changed in patients with other brain tumors such as meningioma or pituitary adenoma. Furthermore, the plasma levels of these three miRNAs in GBM patients treated by operation and chemo-radiation almost revived to normal levels. Finally, we also demonstrated that miR-128 and miR-342-3p were positively correlated with histopathological grades of glioma. These findings suggest that plasma specific miRNAs have potential use as novel biomarkers of glioma and may be useful in clinical management for glioma patients.


1 September 2015 in International Immunopharmacology
Verified
Journal Article
Closed access
HCHongguang Chen
Hongguang Chen
Ke Liang XieKe Liang Xie
Ke Liang Xie
HHHuanzhi Han
Huanzhi Han
YLYuan Li
Yuan Li
LLLingling Liu
Lingling Liu
YYYonghao Yu
Yonghao Yu


28 September 2015 in Inflammation
Verified
Journal Article
Closed access
PDF file
HLHaibin Ling
Haibin Ling
HCHongguang Chen
Hongguang Chen
MWMiao Wei
Miao Wei
XMXiaoyin Meng
Xiaoyin Meng
YYYonghao Yu
Yonghao Yu
Ke Liang XieKe Liang Xie
Ke Liang Xie

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Ke Liang XieKe Liang Xie
Ke Liang Xie
LLLingling Liu
Lingling Liu
YYYonghao Yu
Yonghao Yu
GWGuolin Wang
Guolin Wang
Sepsis is characterized by a severe inflammatory response to infection. It remains a major cause of morbidity and mortality in critically ill patients despite developments in monitoring devices, diagnostic tools, and new therapeutic options. Recently, some studies have found that molecular hydrogen is a new therapeutic gas. Our studies have found that hydrogen gas can improve the survival and organ damage in mice and rats with cecal ligation and puncture, zymosan, and lipopolysaccharide-induced sepsis. The mechanisms are associated with the regulation of oxidative stress, inflammatory response, and apoptosis, which might be through NF-κB and Nrf2/HO-1 signaling pathway. In this paper, we summarized the progress of hydrogen treatment in sepsis.